# Caveolin-1 and Vascular Dysfunction

> **NCT01426529** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Hypertension
- Insulin Resistance

## Interventions

- **DRUG:** Para-aminohippuric Acid
- **DRUG:** Angiotensin II
- **DRUG:** Norepinephrine

## Key facts

- **NCT ID:** NCT01426529
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-10-01
- **Primary completion:** 2026-10-15
- **Final completion:** 2026-10-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01426529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01426529, "Caveolin-1 and Vascular Dysfunction". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01426529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*